β-Cryptoxanthin synergistically enhances the antitumoral activity of oxaliplatin through ΔNP73 negative regulation in colon cancer

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4398-4409

  Millán, Coral San ^a   Soldevilla, Beatriz ^a   Martín, Paloma ^b   Gil Calderón, Beatriz ^c   Compte, Marta ^d   Pérez Sacristán, Belén ^e   Donoso, Encarnación ^f   Peña, Cristina ^c   Romero, Jesús ^g   Granado Lorencio, Fernando ^e   Bonilla, Félix ^h   Domínguez, Gemma ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b Neuropatologia   (Spain)

^c Grupo de señalización celular en cáncer   (Spain)

^d Unidad de inmunología molecular   (Spain)

^e Unidad de Vitaminas   (Spain)

^f Labco   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h Centro de Estudios Biosanitarios   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CRYPTOXANTHIN; OXALIPLATIN; PROTEIN P73; ANTINEOPLASTIC AGENT; CRYPTOXANTHIN; DNA BINDING PROTEIN; ISOPROTEIN; NUCLEAR PROTEIN; PLATINUM COMPLEX; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DELTA NP73 GENE; DOWN REGULATION; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC30; IN VITRO STUDY; IN VIVO STUDY; INHIBITORY CONCENTRATION; INTERVENTION STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; ONCOGENE; PRIORITY JOURNAL; TREATMENT RESPONSE; UPREGULATION; ANIMAL; CELL SURVIVAL; COLONIC NEOPLASMS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CRYPTOXANTHINS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NUCLEAR PROTEINS; ORGANOPLATINUM COMPOUNDS; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945551823     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2027     Document Type: Article

References (50)

1. Nishino H, Tokuda H, Murakoshi M, Satomi Y, Masuda M, Onozuka M, et al. Cancer prevention by natural carotenoids. Biofactors 2000;13: 89-94.
2. Nishino H, Satomi Y, Tokuda H, Masuda M. Cancer control by phytochemicals. Curr Pharm Des 2007;13:3394-9.
3. Nishino H, Murakoshi M, Tokuda H, Satomi Y. Cancer prevention by carotenoids. Arch Biochem Biophys 2009;483:165-8.
4. Tanaka T, Tanaka T, Tanaka M, Kuno T. Cancer chemoprevention by citrus pulp and juices containing high amounts of β-cryptoxanthin and hesperidin. J Biomed Biotechnol [Internet] 2012 [cited 2013 Feb 5];2012. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228311/
5. Granado F, Olmedilla B, Blanco I, Rojas-Hidalgo E. Major fruit and vegetable contributors to the main serum carotenoids in the Spanish diet. Eur J Clin Nutr 1996;50:246-50.
6. Maiani G, Castón MJP, Catasta G, Toti E, Cambrodón IG, Bysted A, et al. Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res 2009;53 Suppl 2:S194-218.
7. MüHlhöfer A. Carotenoids are decreased in biopsies from colorectal adenomas. Clin Nutr 2003;22:65-70.
8. Park S-Y, Nomura AMY, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Carotenoid intake and colorectal cancer risk: the multiethnic cohort study. J Epidemiol 2009;19:63-71.
9. Abnet CC, Qiao Y-L, Dawsey SM, Buckman DW, Yang CS, Blot WJ, et al. Prospective study of serum retinol, β-carotene, β-cryptoxanthin, and lutein/zeaxanthin and esophageal and gastric cancers in China. Cancer Causes Control 2003;14:645-55.
10. Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, et al. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. Br J Cancer 2006;95:406-15.
11. Tamimi RM, Colditz GA, Hankinson SE. Circulating carotenoids, mammographic density, and subsequent risk of breast cancer. Cancer Res 2009; 69:9323.
12. Mignone LI, Giovannucci E, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Hampton JM, et al. Dietary carotenoids and the risk of invasive breast cancer. Int J Cancer 2009;124:2929-37.
13. Zhang X, Spiegelman D, Baglietto L, Bernstein L, Boggs DA, van den Brandt PA, et al. Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies. Am J Clin Nutr 2012;95:713-25.
14. Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat 2012;131:159-67.
15. Siegel EM, Salemi JL, Villa LL, Ferenczy A, Franco EL, Giuliano AR. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. Gynecol Oncol 2010;118:289-94.
16. Klarod K, Hongsprabhas P, Khampitak T, Wirasorn K, Kiertiburanakul S, Tangrassameeprasert R, et al. Serum antioxidant levels and nutritional status in early and advanced stage lung cancer patients. Nutrition 2011;27:1156-60.
17. Stram DO, Yuan J-M, Chan KK, Gao Y-T, Ross RK, Yu MC. β-Cryptoxanthin and lung cancer in Shanghai, China-an examination of potential confounding with cigarette smoking using urinary cotinine as a biomarker for true tobacco exposure. Nutr Cancer 2007;57:123-9.
18. Hung RJ, Zhang Z-F, Rao JY, Pantuck A, Reuter VE, Heber D, et al. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol 2006;176:1192-7.
19. Chiu BC-H, Kwon S, Evens AM, Surawicz T, Smith SM, Weisenburger DD. Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma. Cancer Causes Control 2011;22:1183-95.
20. Kabat GC, Kim MY, Sarto GE, Shikany JM, Rohan TE. Repeated measurements of serum carotenoid, retinol and tocopherol levels in relation to colorectal cancer risk in the Women's Health Initiative. Eur J Clin Nutr 2012;66:549-54.
21. Hu F, Wang Yi B, Zhang W, Liang J, Lin C, Li D, et al. Carotenoids and breast cancer risk: a meta-analysis and meta-regression. Breast Cancer Res Treat 2012;131:239-53.
22. Koushik A, Hunter DJ, Spiegelman D, Anderson KE, Buring JE, Freudenheim JL, et al. Intake of the major carotenoids and the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies. Int J Cancer 2006;119:2148-54.
23. Beydoun HA, Shroff MR, Mohan R, Beydoun MA. Associations of serum vitamin A and carotenoid levels with markers of prostate cancer detection among US men. Cancer Causes Control 2011;22:1483-95.
24. Ollberding NJ, Maskarinec G, Conroy SM, Morimoto Y, Franke AA, Cooney RV, et al. Prediagnostic circulating carotenoid levels and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Blood 2012;119:5817-23.
25. Narisawa T, Fukaura Y, Oshima S, Inakuma T, Yano M, Nishino H. Chemoprevention by the oxygenated carotenoid β-cryptoxanthin of Nmethylnitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 1999;90:1061-5.
26. Tanaka T, Kohno H, Murakami M, Shimada R, Kagami S, Sumida T, et al. Suppression of azoxymethane-induced colon carcinogenesis in male F344 rats by mandarin juices rich in β-cryptoxanthin and hesperidin. Int JCancer 2000;88:146-50.
27. Kohno H, Taima M, Sumida T, Azuma Y, Ogawa H, Tanaka T. Inhibitory effect of mandarin juice rich in β-cryptoxanthin and hesperidin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced pulmonary tumorigenesis in mice. Cancer Lett 2001;174:141-50.
28. Miyazawa K, Miyamoto S, Suzuki R, Yasui Y, Ikeda R, Kohno H, et al. Dietary β-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Oncol Rep 2007;17:297-304.
29. Lian F, Hu K-Q, Russell RM, Wang X-D. β-Cryptoxanthin suppresses the growth of immortalized human bronchial epithelial cells and non-smallcell lung cancer cells and up-regulates retinoic acid receptor β expression. Int J Cancer 2006;119:2084-9.
30. Wu C, Han L, Riaz H, Wang S, Cai K, Yang L. The chemopreventive effect of β-cryptoxanthin from mandarin on human stomach cells (BGC-823). Food Chem 2013;136:1122-9.
31. Baudelet P-H, Gagez A-L, Bérard J-B, Juin C, Bridiau N, Kaas R, et al. Antiproliferative activity of cyanophora paradoxa pigments in melanoma, breast and lung cancer cells. Mar Drugs 2013;11:4390-406.
32. Soldevilla B, Díaz R, Silva J, Campos-Martín Y, Muñoz C, García V, et al. Prognostic impact of DTAp73 isoformlevels and their target genes in colon cancer patients. Clin Cancer Res 2011;17:6029-39.
33. Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother 2012;13:125-37.
34. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
35. Mayer RJ. Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol 2012;30:3325-7.
36. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, et al. DTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. JCO 2006;24:805-15.
37. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
38. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-91.
39. Wu JH, Jones NJ. Assessment of DNA interstrand crosslinks using the modified alkaline Comet Assay. Methods Mol Biol 2012;817:165-81.
40. Das R, Bhattacharya K, Sarkar S, Samanta SK, Pal BC, Mandal C. Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma. Apoptosis 2014;19:149-64.
41. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, et al. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 2010;24:549-60.
42. Ma X, Wang Z. Anticancer drug discovery in the future: an evolutionary perspective. Drug Discov Today 2009;14:1136-42.
43. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol 2007;9:767-76.
44. Guo L, Shen Y-Q, Zhao X-H, Guo L-J, Yu Z-J, Wang D, et al. Curcumin combinedwith oxaliplatin effectively suppress colorectal carcinoma in vivo through inducing apoptosis. Phytother Res 2015; 29:357-65.
45. Howells LM, Sale S, Sriramareddy SN, Irving GRB, Jones DJL, Ottley CJ, et al. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer 2011; 129:476-86.
46. Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S, et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, Xlinked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem 2013;288:23740-50.
47. Xavier CPR, Lima CF, Pedro DFN, Wilson JM, Kristiansen K, Pereira-Wilson C. Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells. J Nutr Biochem 2013;24:706-12.
48. Kumazoe M, Sugihara K, Tsukamoto S, Huang Y, Tsurudome Y, Suzuki T, et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest 2013;123:787-99.
49. Ko J-C, Su Y-J, Lin S-T, Jhan J-Y, Ciou S-C, Cheng C-M, et al. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2010;69:155-64.
50. Banerjee S, Wang Z, Kong D, Sarkar FH. 3,3′-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 2009;69:5592-600.